| BACCO, Di, A BAHLIS, NJ MUNSHI, NC AVET-LOISEAU, H MASSZI, T VITERBO, Luděk POUR, L GANLY, P CAVO, M LANGER, C KUMAR, SK RAJKUMAR, SV KEATS, JJ BERG, D LIN, JH LI, B BADOLA, S SHEN, L ZHANG, JC ESSELTINE, DL LUPTAKOVA, K van DE VELDE, H RICHARDSON a PG MOREAU. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2020, roč. 105, č. 1, s. 35-46. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.13405. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1775024,
author = {Bacco, Di and Bahlis, A and Munshi, NJ and AvetandLoiseau, NC and Masszi, H and Viterbo, T and Pour, Luděk and Ganly, L and Cavo, P and Langer, M and Kumar, C and Rajkumar, SK and Keats, SV and Berg, JJ and Lin, D and Li, JH and Badola, B and Shen, S and Zhang, L and Esseltine, JC and Luptakova, DL and de Velde, K van and Richardson, H and Moreau, PG},
article_location = {Hoboken},
article_number = {1},
doi = {http://dx.doi.org/10.1111/ejh.13405},
keywords = {c-myc Proto-Oncogenes; multiple myeloma; mutation; progression-free survival; RNA sequencing},
language = {eng},
issn = {0902-4441},
journal = {European Journal of Haematology},
note = {Bez afiliace k MU.},
title = {c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma},
volume = {105},
year = {2020}
}
TY - JOUR
ID - 1775024
AU - Bacco, Di - Bahlis, A - Munshi, NJ - Avet-Loiseau, NC - Masszi, H - Viterbo, T - Pour, Luděk - Ganly, L - Cavo, P - Langer, M - Kumar, C - Rajkumar, SK - Keats, SV - Berg, JJ - Lin, D - Li, JH - Badola, B - Shen, S - Zhang, L - Esseltine, JC - Luptakova, DL - de Velde, K van - Richardson, H - Moreau, PG
PY - 2020
TI - c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma
JF - European Journal of Haematology
VL - 105
IS - 1
SP - 35-46
EP - 35-46
PB - Wiley-Blackwell
SN - 09024441
N1 - Bez afiliace k MU.
KW - c-myc Proto-Oncogenes
KW - multiple myeloma
KW - mutation
KW - progression-free survival
KW - RNA sequencing
N2 - Objectives In the TOURMALINE-MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib-lenalidomide-dexamethasone (IRd) showed different magnitudes of progression-free survival (PFS) benefit vs placebo-Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT). Methods RNA sequencing data were used to investigate the basis of these differences. Results The PFS benefit of IRd vs placebo-Rd was greater in patients with tumors expressing high c-MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c-MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c-MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81. Conclusions PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c-MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE-MM1 study. This trial was registered at as: NCT01564537
ER -
BACCO, Di, A BAHLIS, NJ MUNSHI, NC AVET-LOISEAU, H MASSZI, T VITERBO, Luděk POUR, L GANLY, P CAVO, M LANGER, C KUMAR, SK RAJKUMAR, SV KEATS, JJ BERG, D LIN, JH LI, B BADOLA, S SHEN, L ZHANG, JC ESSELTINE, DL LUPTAKOVA, K van DE VELDE, H RICHARDSON a PG MOREAU. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2020, roč.~105, č.~1, s.~35-46. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.13405.
|
